VitalRhythm vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by VitalConnect
VS
by Pathway Labs

AI Verdict

While both tools are FDA-cleared cardiology AI solutions that analyze ECG data, they serve different clinical purposes and workflows. Choose VitalRhythm if you require continuous, remote patient monitoring and real-time arrhythmia detection utilizing wearable biosensors. Opt for EchoNext if you need to analyze standard 12-lead ECGs to screen for structural heart diseases, such as heart failure or valve disease, within a clinical decision support platform.

Choose VitalRhythm if…

Choose VitalRhythm if you need a continuous, wearable remote patient monitoring solution to detect and analyze transient cardiac arrhythmias over an extended period. It is ideal for clinicians who want to integrate patch-based biosensors with cloud-based AI to track real-time ECG signals and capture events like atrial fibrillation or ventricular tachycardia outside the clinic.

View VitalRhythm →

Choose EchoNext if…

Choose EchoNext if you want to screen for hidden structural heart diseases, such as heart failure or valve disease, using standard, non-invasive 12-lead ECGs. It is best suited for providers looking for a point-of-care clinical decision support tool to identify structural risks during routine diagnostic workups without requiring continuous wearable monitoring.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature VitalRhythm EchoNext
Pricing Contact for quote Starts at $600/month
Deployment Cloud-based Available through the OpenEvidence clinical decision support platform.
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Yes AI-estimated Yes AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature VitalRhythm EchoNext
Company VitalConnect Pathway Labs
Tagline Leader in wearable biosensor technology for wireless patient monitoring How's your heart?
Target Size Not specified EchoNext is designed for broad access, from major hospitals to community practices.
Headquarters Not specified New York, USA
Primary Input Data Source Continuous ECG signal analysis via VitalPatch biosensor Standard 12-lead ECGs

Videos

Demos, reviews, and walkthroughs featuring VitalRhythm and EchoNext.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

VitalRhythm is designed for continuous cardiac arrhythmia detection (such as atrial fibrillation, AV block, SVT, VT, and pauses) using continuous ECG signal analysis. In contrast, EchoNext analyzes standard 12-lead ECGs to detect hidden structural heart diseases, including heart failure risk, valve disease, and pulmonary hypertension indicators.
While both tools support Cardiology, Hospital Medicine, and Internal Medicine, VitalRhythm is tailored for continuous remote patient monitoring (RPM) workflows. EchoNext expands its specialty fit to include Family Medicine, making it highly suitable for broad primary care and community practice screening.
VitalRhythm supports non-urgent clinical decision-making by continuously monitoring patients remotely and displaying detected arrhythmias for professional review. EchoNext acts as a non-invasive diagnostic support tool, analyzing standard ECGs to screen for silent structural risks during routine or diagnostic patient workups.
VitalRhythm utilizes a proprietary deep learning-based algorithm to perform continuous ECG signal analysis from its paired wearable biosensor. EchoNext uses FDA-cleared AI-powered ECG analysis to identify structural heart disease markers from standard 12-lead ECGs.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.